GlobalData on MSN3d
Sanofi’s Sarclisa combo approved in China for multiple myeloma
Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...
L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker
Cosmetics giant L’Oreal SA is selling a €3 billion ($3.1 billion) stake in Sanofi back to the French drugmaker, cashing in ...
L’Oreal to sell $3.1 billion stake in Sanofi back to pharma group
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Sanofi: Positioned for Strong Growth with Conservative Guidance and Strategic Initiatives
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...
Sanofi’s Strong Growth Prospects and Strategic Initiatives Justify Buy Rating
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
American Association of Individual Investors6d
Which Is a Better Investment, Sanofi or Zoetis Inc. Stock?
Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both ...
Bredin, Cleary Guide Sanofi’s €3B Share Buyback From L’Oreal
In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...
Cosmetics Business3d
L’Oréal sells €3 billion of Sanofi stock back to pharmaceutical group
The beauty giant said the transaction – selling approximately 29.6 million of its Sanofi shares for €101.5 per share – will ...
PharmiWeb3d
Sanofi announces buy back of shares from L’Oréal
Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program announced on January 30, 2025. It is ...
L'ORÉAL: Agreement Between L'Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L'Oréal
AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASEBY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL Clichy, February 3, 2025 - L'Oréal announces today that it has agreed to sell approximately ...
BioSpace7d
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
The Pharma Letter2d
Mitem Pharma acquires Flisint rights from Sanofi
French drugmaker Mitem Pharma, which is dedicated to drugs of major therapeutic interest (DMTI), today revealed that has ...